IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Denmark

  • ID: 1408479
  • Report
  • Region: Denmark
  • 46 Pages
  • IMS Health
1 of 3

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets.

This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Note: Product cover images may vary from those shown
2 of 3

DENMARK

1. Healthcare System

  • Facts & Figures
  • Market Indicators
  • Provision & Funding
  • Healthcare System
  • Healthcare Funding
  • Provision of Care
  • Private Insurance

2. Pricing

  • Prescription Drugs
  • Generic Drugs
  • Hospital Drugs
  • Pricing Regulations
  • Actual Prices
  • Tenders
  • OTC Drugs

3. Reimbursement

  • Admission to Reimbursement
  • Application Process
  • Decision Making
  • General Reimbursement
  • Individual Reimbursement
  • Reimbursement Categories
  • Reimbursement Prices
  • Multisource Products
  • Single Source Products
  • Hospital Reimbursement
  • Hospital Formularies
  • Medicine Council
  • Council for the Use of High-Cost Hospital Medicines (RADS)
  • The Co-ordination Council for the Use of Hospital Medicines (KRIS)
  • Hospital Funding
  • Changes in Reimbursement Status
  • Reimbursement List Updates
  • Reimbursement Reassessments
  • New Presentations and Indications
  • Changes in Reimbursement Prices
  • Price Changes
  • Primary Care Price Cap Agreement
  • Fortnightly Price List

4. Pharmacoeconomic

  • Pharmacoeconomic Requirements
  • Retail Drugs
  • Hospital Drugs

5. Price Build Up

  • Wholesalers
  • Margins
  • Background
  • Retail Pharmacies
  • Margins
  • Discounts
  • Background
  • E-pharmacy
  • Dose Dispensing
  • Dispensing Doctors
  • Sales Tax

6. Cost Containment

  • Industry Paybacks
  • Promotional Costs
  • Patient Co-payments
  • Pharmaceuticals
  • Healthcare
  • Supplementary Insurance
  • Prescribing Controls
  • National Measures
  • Regional Measures
  • Generics
  • Substitution
  • Rx-to-OTC Switches
  • Status Changes
  • Two-year Period of Pharmacy-only Sales
  • Liberalised OTC Sales
  • Direct Patient Access to OTCs
  • Parallel Trade

7. Future Developments

  • Outlook

8. Names & Addresses

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll